Local effects of malignancy on bone

Sue A. Brown, Gregory A. Clines, Theresa Guise

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Skeletal-related complications occur commonly in many solid tumors including breast, prostate and lung cancer as well as multiple myeloma. In addition, malignancies and their associated treatment may result in bone loss or osteoporosis. This review will focus solely on recent data associated with metastatic bone disease with a focus on breast cancer, prostate cancer and multiple myeloma. Bone loss or osteoporosis associated with cancer will be covered in a separate article in this issue. RECENT FINDINGS: Recent progress in understanding the pathophysiology of bone metastases has pointed to several novel pathways: transforming growth factor β; receptor activator of nuclear factor β ligand and osteoprotegerin; and Wnt signaling pathways and associated factors such as dickkopf-1 and endothelin-1. SUMMARY: The identification of new pathways is important in metastatic bone disease from cancer and has allowed for the development of novel therapeutics aimed at preventing the devastating complications of bone metastases. Bisphosphonates remain the predominant therapy in use for the treatment and prevention of skeletal-related adverse effects from cancer.

Original languageEnglish (US)
Pages (from-to)436-441
Number of pages6
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume14
Issue number6
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Bone and Bones
Prostatic Neoplasms
Bone Diseases
Multiple Myeloma
Osteoporosis
Neoplasms
Breast Neoplasms
Neoplasm Metastasis
RANK Ligand
Bone Neoplasms
Wnt Signaling Pathway
Diphosphonates
Transforming Growth Factors
Endothelin-1
Cytoplasmic and Nuclear Receptors
Lung Neoplasms
Therapeutics

Keywords

  • Bisphosphonates
  • Bone
  • Cancer
  • Metastases

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

Local effects of malignancy on bone. / Brown, Sue A.; Clines, Gregory A.; Guise, Theresa.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 14, No. 6, 12.2007, p. 436-441.

Research output: Contribution to journalArticle

Brown, Sue A. ; Clines, Gregory A. ; Guise, Theresa. / Local effects of malignancy on bone. In: Current Opinion in Endocrinology, Diabetes and Obesity. 2007 ; Vol. 14, No. 6. pp. 436-441.
@article{8fe1bb13069a44788cf29715e82fa77d,
title = "Local effects of malignancy on bone",
abstract = "PURPOSE OF REVIEW: Skeletal-related complications occur commonly in many solid tumors including breast, prostate and lung cancer as well as multiple myeloma. In addition, malignancies and their associated treatment may result in bone loss or osteoporosis. This review will focus solely on recent data associated with metastatic bone disease with a focus on breast cancer, prostate cancer and multiple myeloma. Bone loss or osteoporosis associated with cancer will be covered in a separate article in this issue. RECENT FINDINGS: Recent progress in understanding the pathophysiology of bone metastases has pointed to several novel pathways: transforming growth factor β; receptor activator of nuclear factor β ligand and osteoprotegerin; and Wnt signaling pathways and associated factors such as dickkopf-1 and endothelin-1. SUMMARY: The identification of new pathways is important in metastatic bone disease from cancer and has allowed for the development of novel therapeutics aimed at preventing the devastating complications of bone metastases. Bisphosphonates remain the predominant therapy in use for the treatment and prevention of skeletal-related adverse effects from cancer.",
keywords = "Bisphosphonates, Bone, Cancer, Metastases",
author = "Brown, {Sue A.} and Clines, {Gregory A.} and Theresa Guise",
year = "2007",
month = "12",
doi = "10.1097/MED.0b013e3282f15419",
language = "English (US)",
volume = "14",
pages = "436--441",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Local effects of malignancy on bone

AU - Brown, Sue A.

AU - Clines, Gregory A.

AU - Guise, Theresa

PY - 2007/12

Y1 - 2007/12

N2 - PURPOSE OF REVIEW: Skeletal-related complications occur commonly in many solid tumors including breast, prostate and lung cancer as well as multiple myeloma. In addition, malignancies and their associated treatment may result in bone loss or osteoporosis. This review will focus solely on recent data associated with metastatic bone disease with a focus on breast cancer, prostate cancer and multiple myeloma. Bone loss or osteoporosis associated with cancer will be covered in a separate article in this issue. RECENT FINDINGS: Recent progress in understanding the pathophysiology of bone metastases has pointed to several novel pathways: transforming growth factor β; receptor activator of nuclear factor β ligand and osteoprotegerin; and Wnt signaling pathways and associated factors such as dickkopf-1 and endothelin-1. SUMMARY: The identification of new pathways is important in metastatic bone disease from cancer and has allowed for the development of novel therapeutics aimed at preventing the devastating complications of bone metastases. Bisphosphonates remain the predominant therapy in use for the treatment and prevention of skeletal-related adverse effects from cancer.

AB - PURPOSE OF REVIEW: Skeletal-related complications occur commonly in many solid tumors including breast, prostate and lung cancer as well as multiple myeloma. In addition, malignancies and their associated treatment may result in bone loss or osteoporosis. This review will focus solely on recent data associated with metastatic bone disease with a focus on breast cancer, prostate cancer and multiple myeloma. Bone loss or osteoporosis associated with cancer will be covered in a separate article in this issue. RECENT FINDINGS: Recent progress in understanding the pathophysiology of bone metastases has pointed to several novel pathways: transforming growth factor β; receptor activator of nuclear factor β ligand and osteoprotegerin; and Wnt signaling pathways and associated factors such as dickkopf-1 and endothelin-1. SUMMARY: The identification of new pathways is important in metastatic bone disease from cancer and has allowed for the development of novel therapeutics aimed at preventing the devastating complications of bone metastases. Bisphosphonates remain the predominant therapy in use for the treatment and prevention of skeletal-related adverse effects from cancer.

KW - Bisphosphonates

KW - Bone

KW - Cancer

KW - Metastases

UR - http://www.scopus.com/inward/record.url?scp=35848946353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848946353&partnerID=8YFLogxK

U2 - 10.1097/MED.0b013e3282f15419

DO - 10.1097/MED.0b013e3282f15419

M3 - Article

VL - 14

SP - 436

EP - 441

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 6

ER -